Clinical trials with antibodies to checkpoint inhibitors revealed that the programmed death 1 (PD1) pathway is a major contributor to immune suppression in melanoma, renal cell carcinoma, and non-small cell lung cancer patients since antibodies to either the receptor on T cells (PD1) or the ligand for the receptor (PDL1) significantly increased patient survival. This evidence concerns the gene CD274 and melanoma.